Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Significant survival gains with atezolizumab for NSCLC

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1926

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Dr Barlesi speaks with ecancertv at ESMO 2016 about results from the OAK study, in which 1225 non-small cell lung cancer patients who had previously received treatment were stratified based on PD-L1 status and treatment history, then received either PD-1 inhibitor atezolizumab or standard therapy docetaxel.

He describes the improvements in patients median survival across both groups, though reports a 56% greater response for patients with the highest levels of PD-L1 expression, and considers the treatment duration and associated toxicities of both arms in the trial.

Press conference footage of Dr Barlesi announcing these results is available here. 

Further details are available through news coverage here.

PD-1/PD-L1 targeting in lung cancer was also the focus of ESMO 2016 presentations from ESMO 2016 presentations from Dr Martin Reck and Dr Corey Langer, who spoke with ecancer about their work.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation